Peptides have become a powerful tool in the changing field of medical weight management, especially for women who struggle with hormonal weight gain. Due to a woman's biology, which ranges from the insulin resistance linked to Polycystic Ovary Syndrome (PCOS) to the metabolic slowdown during perimenopause and menopause, conventional eating might seem like an uphill fight. Choosing the appropriate peptide treatment is critical for this reason, as it may cooperate with your body's specific hormonal environment rather than opposing it. MHRA-approved GLP-1 medications are the best choice since clinical research indicates that they result in higher average weight loss in women than in men.
However, the word "peptides" is now used to describe two very different groups: uncontrolled research chemicals sold online with significant risks and regulated, evidence-based prescription medications. This article outlines the reasons why the best peptides for weight loss for females are those that are prescribed under a regulated medical framework.
Women Experience Greater Effectiveness
The clinical evidence is unequivocal: second-generation anti-obesity drugs help women lose more weight than men. A genuine study involving 269 individuals revealed that 78% of the participants were women and that both tirzepatide and semaglutide caused a considerable decrease in visceral fat, waist circumference, BMI, and weight. This indicates that these therapies are extremely beneficial for feminine physiology. You are opting for a treatment with established outcomes designed for women's physiology when you select a regulated drug.
Deals with Hormonal Weight Gain
Women often put on weight because of hormones. Peri menopause and menopause reduce estrogen levels, which slows metabolism and causes fat to be stored in the stomach, whereas disorders like PCOS cause insulin resistance, making it challenging to manage weight. GLP-1 peptides are successful even when hormones are changing because they operate independently of estrogen levels on the hunger control system. A meta-analysis found that compared to metformin or placebo, GLP-1 receptor agonists substantially lower body weight, waist circumference, and BMI in women who have PCOS.
Options in the UK That Are Regulated and Licensed
Just three peptide-based drugs are approved by the MHRA for weight loss in the UK: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro). Without a valid prescription or without public advertising, they are exclusively available by prescription. The highest average weight loss is seen with tirzepatide, a dual GLP-1/GIP receptor agonist, at 22. 5% at 72 weeks, followed by semaglutide at 14. 9% at 68 weeks. These selections guarantee safety, quality, and demonstrated effectiveness.
Proven Outcomes From Clinical Trials
Supported by extensive clinical studies, licensed peptides are available. Semaglutide was found to cause a 14. 9% decrease in body weight after 68 weeks in the STEP 1 study, whereas tirzepatide was found to induce up to 20. 9% weight reduction at 72 weeks in the SURMOUNT-1 trial.
Perimenopausal women have also seen excellent outcomes from oral semaglutide. Robust, peer-reviewed data, not anecdotal allegations, are presented here. However, unlicensed peptides like BPC-157 or AOD-9604 are not licensed as medicines anywhere and have no evidence from human clinical studies that they cause weight loss.
Learning about the Safety Profile
With any medical procedure, safety is essential. GLP-1 peptides that have received regulatory approval have established side effects, most frequently nausea and vomiting, especially during dose titration. Nevertheless, they are administered with medical oversight in order to manage these consequences.
On the other hand, unregulated peptides are very dangerous because they can lead to abscess development, infections, immunological reactions, improper dosing, and contamination. Additionally, women report a higher rate of negative side effects with GLP-1s, emphasising the necessity of cautious, supervised prescribing.
PCOS Treatment Assistance
Weight loss is a common therapeutic aim for women with PCOS, but it may be very difficult. GLP-1 receptor agonists have been demonstrated to successfully lower body weight, BMI, and insulin resistance in patients with PCOS. Because improving insulin sensitivity directly tackles one of the underlying causes of weight gain linked to PCOS, this is important.
Initial health screenings are provided by services such as SheMed before any prescriptions are given, guaranteeing that the therapy is customised to a woman's particular biology. These services are designed specifically for women.
Targeted Assistance for Perimenopause and Menopause
Fat storage is altered by decreasing oestrogen levels during perimenopause and menopause, which also increases appetite and slows metabolism. Because they affect the brain's appetite centre regardless of estrogen, GLP-1 drugs are helpful in this population.
Women at all menopause stages lost 15–18% of their body weight on oral semaglutide, according to OASIS 4 data. According to new studies, salmon protein hydrolysate peptides show potential, with trials demonstrating moderate weight loss (6-7%) and an examination for thofability to alleviate menopausal symptoms.
Conclusion
Selecting the top peptides for weight loss for women entails choosing a treatment that is supported by science, regulated, and supervised clinically. Although it's understandable why people want to lose weight, utilising unapproved research peptides poses serious legal and health concerns.
Women may utilise the confirmed efficacy of approved GLP-1 medications to safely address hormonal weight gain, enhance metabolic health, and generate long-lasting outcomes by collaborating with a doctor. This evidence-based approach protects your long-term health as well as ensuring the treatment's efficacy.
Visit Velog for more informative blogs.
